NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
22 trialsNCT03734692 2026-02-12
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT06040970 2025-12-02
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT04956640 2025-09-25
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Recruiting
NCT02432378 2025-06-19
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT06859775 2025-06-06
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT01088347 2024-04-19
Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
University Medical Center Groningen
Phase 1/2 Completed
NCT06241235 2024-04-02
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT00889733 2024-03-26
OVHM-01
University Health Network, Toronto
Phase 1/2 Terminated
NCT04938583 2023-10-17
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Unknown
NCT01076400 2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT04851834 2022-12-20
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
Phase 1/2 Terminated
NCT02604784 2020-09-17
PI-CaP
Fondazione del Piemonte per l'Oncologia
Phase 1/2 Completed
NCT01230996 2019-04-24
DEPICT
Barts & The London NHS Trust
Phase 1/2 Completed
NCT01083537 2019-02-15
Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
University Health Network, Toronto
Phase 1/2 Terminated
NCT00091377 2016-07-14
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
MEI Pharma, Inc.
Phase 1/2 Completed
NCT02095119 2015-04-14
A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer
National Institute of Cancerología
Phase 1/2 Completed
NCT00012012 2015-01-07
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00023660 2013-11-19
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00002559 2013-07-02
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00003379 2013-05-27
Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer
GOG Foundation
Phase 1/2 Completed
NCT00551122 2013-01-23
GemTIP
University of Southampton
Phase 1/2 Unknown